Primary biliary cholangitis is often associated with diagnoses of osteoporosis, sarcopenia, or vertebral fracture among women, with diagnosis of one condition predicting the diagnosis of another.
The FDA has identified 25 cases of serious liver injury leading to liver decompensation or liver failure associated with Ocaliva in PBC patients with compensated or decompensated cirrhosis.
This study evaluated the safety, feasibility, and QoL of patients after endoscopic ultrasonography-guided biliary drainage with lumen-apposing metal stents, after failed ERCP.
When diagnosing indeterminate biliary strictures, digital single-operator cholangioscopy (DSOC)-guided biopsy has demonstrated safety, efficacy, and higher sensitivity than standard endoscopic retrograde cholangiopancreatography.
Study investigators concluded that although the optimum treatment course for common bile duct stones has not yet been determined, “ERCP for CBD stone clearance involves multiple interventions, prolonged treatment, causes post procedure morbidity and high treatment costs.
Nearly half of patients with early-stage PBC progress to a more severe stage within 5 years. Progression is associated with increased risk of a clinical event, so surveillance is important for patients with early-stage PBC.
Researchers conducted a retrospective cohort study to determine the clinical features of pediatric patients with PSC in a Japanese cohort to evaluate long-term outcomes. They discovered that primary sclerosing cholangitis (PSC)-autoimmune hepatitis overlap is the primary phenotype linked to poor long-term outcomes.
The researchers observed an increased risk for acute gallbladder or biliary disease with liraglutide versus placebo (hazard ratio, 1.60). Similar findings were seen for each of the four categories of gallbladder- or biliary tract-related events (uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis with/without gallbladder stones, and biliary obstruction).
